117 Generic Drug Variants Pass Consistency Evaluation in February; Shijiazhuang Siyao Leads, Lunan Pharmaceutical and Two Others Emerge as Top Filers
Lunan Pharmaceutical
Comprehensive Pharmaceutical Group
Shijiazhuang No.4 Pharmaceutical Co.,Ltd.
Manufacturers and Service Providers of Chemical Drugs and Traditional Chinese Medicine
According to the statistics from the Pharma Intelligence Cloud database, in February 2024, the CDE accepted a total of 332 new registration classification generic drug applications and 79 consistency evaluation supplementary applications, involving over 300 pharmaceutical companies. In terms of the number of declared varieties, Kangrui Huatai, Zhejiang Deep Sea Pharmaceutical, and Lunan Pharmaceutical stood out.(By Group)Three companies stood out remarkably, jointly becoming the biggest "competitive kings" of the month. All three companies applied for nine drugs each.
In terms of passing the review, FebruaryA total of 117 varieties(177 Specifications)Passed/Deemed to have passed the consistency evaluation, involving 119 enterprises. Shijiazhuang No.4 Pharmaceutical Co., Ltd. has reaped abundant fruits, leading the list of evaluations passed this month.
Lunan Pharmaceutical and Other 3 Major Pharma Leaders Dominate, Becoming the Biggest Cost King of the Month
In February, the CDE handled 332 new registration classifications for generic drug applications and 79 supplemental applications for consistency evaluations, involving over 300 pharmaceutical companies. The most concentrated field of applications this month wasCardiovascular System Medications, followed bySystemic Anti-Infective Drugs。
Screenshot source: PharmaCloud China Drug Evaluation Database - Global Analysis
Compared with the previous month's corporate reporting situation, this month Kangrui Huatai, Zhejiang Shenhai Pharmaceutical, and Lunan Pharmaceutical(Group Plan)Three companies stood out remarkably, jointly becoming the biggest "contenders" of the month. All three companies submitted applications for nine drugs each, excelling in the competition within the generic drug application field, and are tied for the top position this month.
February Application Status of Kangrui Huatai, Zhejiang Deep Sea Pharmaceuticals, and Lunan Pharmaceutical
Data Source: PharmaCloud China Drug Evaluation Database
From the perspective of the accepted varieties,Diprophylline Injection, Compound Potassium Phosphate Injection, Metoclopramide Hydrochloride InjectionThe number of relevant applications for three varieties is the highest.
Screenshot source:PharmCube China Drug Evaluation Database - Global Analysis
Eight Major Varieties Receive First Approval, Shijiazhuang No.4 Pharmaceutical Co.,Ltd. Leads the Approval List
February: 117 varieties in total(177 specifications)Passed/Deemed to have passed the consistency evaluation, involving 119 enterprises. Shijiazhuang No.4 Pharmaceutical Co.,Ltd. has reaped a bumper harvest, leading the list of evaluations passed this month with three varieties. They are followed by Sichuan Pharmaceutical Preparation, Chongqing Yaoyou Pharmaceutical and 11 other pharmaceutical companies, each having two varieties passed the evaluation.
Data Source:PharmCube Approved Drug Summary Database
Among the varieties that have passed the evaluation,Piracetam InjectionThe number of companies that have passed the review is the highest, reaching 3.Sodium Penicillin for Injection, Cefoperazone Sodium and Sulbactam Sodium for Injection, Oseltamivir Phosphate Capsules, Potassium Chloride Injection, Lurasidone Hydrochloride Tablets, Cytidine Diphosphate Choline Sodium InjectionAll 13 varieties have been approved by two companies.
In terms of the first batch of qualified varieties, there are a total of8A variety welcomes the first approval, involvingFuyuan Pharmaceutical, Sinopharm Yixin Pharmaceutical, Double-Crane Pharmaceutical, Shanghai Xuantai Pharmaceuticaletc.MoreChinese pharmaceutical enterprises. Among themFurosemide Oral Solution, Mesalazine Enteric-Coated Sustained-Release Tablets2A variety of products have ushered in their first generic versions.
Data Source:PharmCubeSummary of Approved DrugsDatabase
END
Reply to the keyword "Report", access dozens of exclusive reports produced by Yaorongyun
Reply to the keyword "CSCO", Obtain 2023 CSCO Guidelines
Reply to the keyword "ASCO", Obtain 2023 ASCO Abstract by Cancer Type
Reply to the keyword "First Generic in 2022", obtain the list of first generic drugs approved in 2022
Reply to the keyword "Medical Insurance", obtain the 2022 medical insurance catalog
Contact us to experience more professional services from PharmaCloud. | ||||
WillDiscussion CombineWork | GardenDistrict TakeMission | Database Consultation | Customization Service | Media Cooperation |
